Patents by Inventor James Veltmeyer
James Veltmeyer has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).
-
Publication number: 20240366677Abstract: The present disclosure provides means of inhibition and/or treating aneurysms and other degenerated blood vessels through administration of regenerative cell derived exosomes, and/or regenerative cell derived apoptotic bodies. In one particular embodiment vessel regeneration is increased through administration of stem cell exosomes/or stem cell apoptotic bodies. Other embodiments include regeneration of vessels prone to aneurysms, repairing aneurysms of vessels, or acceleration of endothelialization after stent placement. Provided within the invention are methods of rejuvenating properties of said vessels associated with physiological health, examples of which include appropriate production of anti-coagulating/clotting factors, control of angiogenesis, and appropriate revascularization of injured tissue.Type: ApplicationFiled: May 1, 2024Publication date: November 7, 2024Applicant: Therapeutic Solutions International, Inc.Inventors: Thomas Ichim, Timothy G. Dixon, James Veltmeyer
-
Publication number: 20240269148Abstract: Parallels between pregnancy and cancer have been historically made, however, the ability to leverage abortogenic immunity against neoplasia has not been widely examined. The current invention provides means of suppressing tumor associated immune inhibition through administration of progesterone and/or glucocorticoid receptor antagonists such as RU-486. In one embodiment the invention provides the concurrent utilization RI-486 and anti-angiogenic immunotherapy. In another embodiment, abortogenic inhibitors of immunity such as indolamine 2,3 dioxygenase are administered together with RU-486 and/or anti-angiogenic immunotherapy. Various antiangiogenic agents can be utilized in the practice of the invention including the ValloVax immunotherapy and/or the StemVacs-V therapy.Type: ApplicationFiled: February 15, 2024Publication date: August 15, 2024Applicant: Therapeutic Solutions International, Inc.Inventors: Thomas E. Ichim, Famela Ramos, James Veltmeyer, Timothy G. Dixon
-
Patent number: 12011462Abstract: Disclosed are novel means of enhancing mesenchymal stem cell regenerative activities including, intra alia, production from pulmonary leakage and suppression of scar tissue formation by co-administration with T regulatory cells. In some embodiments the invention provides an interaction between T regulatory cells and mesenchymal stem cells in which T regulatory cells stimulate upregulation of mesenchymal stem cell activity in a GITR dependent manner.Type: GrantFiled: September 22, 2022Date of Patent: June 18, 2024Assignee: Therapeutic Solutions International, IncInventors: Thomas E. Ichim, Famela Ramos, James Veltmeyer, Timothy G. Dixon, Feng Lin, Kalina O'Connor
-
Patent number: 11957727Abstract: Disclosed are means, methods, and therapeutic compositions for prevention of memory loss during situations of neuroinflammation. In one embodiment the invention teaches administration of the therapeutic combination of ingredients comprising of pterostilbene, Nigella sativa, sulforaphane, and epigallocatechin-3-gallate (EGCG) to a mammal suffering from inflammation in order to preserver memory function.Type: GrantFiled: August 5, 2021Date of Patent: April 16, 2024Assignee: Therapeutic Solutions International, IncInventors: Thomas E. Ichim, Famela Ramos, James Veltmeyer, Timothy G. Dixon
-
Publication number: 20230201268Abstract: Disclosed are means, methods and compositions useful for the prevention, inhibition, and regression of a neoplastic growth through altering the tumor microenvironment using neurons, derivatives from neurons, and neuromodulating agents and/or energy-based approaches. In one embodiment allogeneic neuronal cells are generated from pluripotent stem cells and administered locally in tumor microenvironment to induce an alteration tumor growth directly or in combination with other therapeutic approaches. In some embodiments exosomes from allogeneic neuronal cells are administered as a therapeutic agent. In other embodiments of the invention re-innervation of tumor tissue and/or alteration of neurons innervating said tumor issue is performed by administration of neurotrophic factors.Type: ApplicationFiled: December 16, 2022Publication date: June 29, 2023Inventor: James Veltmeyer
-
Publication number: 20230192901Abstract: Disclosed are means, methods and compositions of matter useful for treatment of inflammatory pulmonary diseases such as COVID-19 through administration of agents that facilitate interaction between immune modulatory cells and endogenous pulmonary progenitor cells. In one embodiment a bispecific antibody capable of facilitating the interaction between CD25 on T regulatory cells and CD47 on pulmonary epithelial stem cells is described.Type: ApplicationFiled: November 17, 2022Publication date: June 22, 2023Applicant: Therapeutic Solutions International, Inc.Inventors: Thomas E. Ichim, Famela Ramos, James Veltmeyer, Timothy G. Dixon
-
Publication number: 20230107484Abstract: Disclosed are methods of reducing lung inflammation in acute respiratory distress syndrome elicited by various factors such as COVID-19 infection by reduction of neutrophil extracellular trap formation through administration of mesenchymal stem cells and/or exosomes thereof. The invention provides means of inhibiting neutrophil release of extracellular traps by mesenchymal stem cells and/or exosomes derived from said mesenchymal stem cells. Additionally, synergies are provided between mesenchymal stem cells and/or exosomes derived from mesenchymal stem cells and agents approaches which reduce neutrophil extracellular trap formation.Type: ApplicationFiled: October 4, 2022Publication date: April 6, 2023Applicant: Therapeutic Solutions International, Inc.Inventors: Thomas E. Ichim, Famela Ramos, James Veltmeyer, Timothy G. Dixon, Feng Lin, Wais Kaihani
-
Publication number: 20230090980Abstract: Disclosed are novel means of enhancing mesenchymal stem cell regenerative activities including, intra alia, production from pulmonary leakage and suppression of scar tissue formation by co-administration with T regulatory cells. In some embodiments the invention provides an interaction between T regulatory cells and mesenchymal stem cells in which T regulatory cells stimulate upregulation of mesenchymal stem cell activity in a GITR dependent manner.Type: ApplicationFiled: September 22, 2022Publication date: March 23, 2023Applicant: Therapeutic Solutions International, Inc.Inventors: Thomas E. Ichim, Famela Ramos, James Veltmeyer, Timothy G. Dixon, Feng Lin, Kalina O'Connor
-
Publication number: 20230085607Abstract: Disclosed are novel mechanisms of action of ivermectin therapy as related to treatment of COVID-19 and means of augmenting therapeutic activities by co-administration with one or more of the following: pterostilbene, thymoquinone, epigallocatechin-3-gallate, and sulforaphane. In one embodiment the invention provides enhanced reduction of inflammation induced pulmonary leakage without augmenting immune suppressive mechanisms.Type: ApplicationFiled: September 13, 2022Publication date: March 16, 2023Applicant: Therapeutic Solutions International, Inc.Inventors: Thomas E. Ichim, Famela Ramos, James Veltmeyer, Timothy G. Dixon, Feng Lin, Wais Kaihani
-
Publication number: 20230010501Abstract: Disclosed are means, methods and compositions of matter for treatment Parkinson's Disease through concurrent immune modulation and regenerative means. In one embodiment Parkinson's Disease is treated by augmentation of T regulatory cell numbers and/or activity while concurrently providing regenerative cells such as mesenchymal stem cells, and/or dopamine secreting cells. In one embodiment administration of immunoglobulins such as IVIG together with low dose interleukin-2 and/or low dose naltrexone is disclosed as a preparatory means prior to administration of therapeutic cells such as stem cells. Other therapeutic means utilized in an adjuvant manner are also provided for hormonal rebalancing, transcranial magnetic stimulation, and deep brain stimulation.Type: ApplicationFiled: July 6, 2022Publication date: January 12, 2023Applicant: Therapeutic Solutions International, Inc.Inventors: Thomas E. Ichim, Timothy G. Dixon, James Veltmeyer, Kalina O'Connor
-
Publication number: 20220403330Abstract: Disclosed are novel means, protocols, and compositions of matter for eliciting an immune response against blood vessels supplying neoplastic tissue. In one embodiment pluripotent stem cells are transfected with one or more genes capable of eliciting immunity. In some embodiments such genes are engineered under control of specific promoters to allow for various specificities of activity. In one specific embodiment pluripotent stem cells engineered to endow properties capable of inducing expression of the ?-Gal epitope (Gal?1,3Gal?1,4G1cNAc-R).Type: ApplicationFiled: May 19, 2022Publication date: December 22, 2022Applicant: Therapeutic Solutions International, Inc.Inventors: Thomas E. Ichim, Famela Ramos, James Veltmeyer, Timothy G. Dixon, Feng Lin
-
Publication number: 20220395540Abstract: Disclosed are means, methods and compositions of matter useful for treatment of lung inflammation associated with viral and bacterial infections, as well as with systemic inflammation, through administration of umbilical cord blood derived plasma-based compositions. In one embodiment the invention teaches administration of umbilical cord blood plasma together with pterostilbene, and/or sulforaphane, and/or thymoquinone, and/or Epigallocatechin gallate (EGCG) and/or n-acetylcysteine in an aerosolized manner to patients suffering from COVID-19 associated pulmonary deficiencies. In another embodiment, umbilical cord blood plasma is administered with immune stimulatory agents in order to concurrently inhibit propagation of viral load in the lung while suppressing pulmonary deficiencies.Type: ApplicationFiled: June 9, 2021Publication date: December 15, 2022Applicant: THERAPEUTIC SOLUTIONS INTERNATIONAL, INC.Inventors: James Veltmeyer, Thomas E. Ichim, Timothy G. Dixon
-
Publication number: 20220370561Abstract: Disclosed are compositions of matter, therapeutics, and protocols useful for reduction and/or reversion of pulmonary fibrosis. In one specific embodiment lithium chloride is administered together with a regenerative cell in a patient suffering from, or at risk of pulmonary fibrosis. In one embodiment said lithium chloride is administered as an adjuvant to a regenerative therapy, wherein said regenerative therapy is a gene therapy, a protein therapy, a cell therapy, or a tissue transplant. In one embodiment lithium chloride, or a salt thereof is utilized alone, or with a regenerative means, to evoke preservation and/or elongation of telomere length in pulmonary tissue.Type: ApplicationFiled: May 19, 2022Publication date: November 24, 2022Applicant: Therapeutic Solutions International, Inc.Inventors: Thomas E. Ichim, Timothy G. Dixon, Wals Kaihani, Famela Ramos, James Veltmeyer
-
Publication number: 20220370499Abstract: Disclosed are novel means, protocols, and compositions of matter for creating targeted immune responses and/or induction of immunological memory towards the tumor vasculature. In one embodiment pluripotent stem cells are transfected with one or more genes capable of eliciting immunity, induced to differentiate into endothelial-like cells which resemble the tumor endothelial cells, and utilized as a vaccine. In some embodiment's genes are engineered under control of specific promoters to allow for various specificities of activity. In one specific embodiment pluripotent stem cells engineered to endow properties capable of inducing expression of the ?-Gal epitope (Gal?1,3Gal?1,4GlcNAc-R). Addition of adjuvants to enhance antigen presentation of the vaccine composition, as well as means of stimulating systemic enhancement of circulating endothelial specific T cells are also disclosed.Type: ApplicationFiled: May 19, 2022Publication date: November 24, 2022Applicant: Therapeutic Solutions International, Inc.Inventors: Thomas E. Ichim, Famela Ramos, James Veltmeyer, Timothy G. Dixon, Feng Lin, Wais Kaihani
-
Patent number: 11504410Abstract: Disclosed are means, compositions of matter, and protocols useful for neuroprotection and neuroregeneration. In one embodiment the invention provides administration of pterostilbene alone or in combination with other ingredients to induce neuroprotection and/or neuroregeneration. The invention teaches protection/regeneration in conditions associated with neurological inflammation and/or other congenital or acquired neurodegenerative diseases.Type: GrantFiled: July 28, 2021Date of Patent: November 22, 2022Assignee: Therapeutic Solutions International, Inc.Inventors: Thomas E. Ichim, Timothy G. Dixon, James Veltmeyer
-
Publication number: 20220323547Abstract: Disclosed are compositions of matter, protocols and treatment means for reducing and/or preventing opioid addiction. In one embodiment the invention teaches intranasal administration of umbilical cord blood plasma, or extracts thereof, together with pterostilbene or pterostilbene containing nanoparticles, and/or oxytocin, and/or human chorionic gonadotropin.Type: ApplicationFiled: April 13, 2022Publication date: October 13, 2022Applicant: Therapeutic Solutions International, Inc.Inventors: Thomas E. Ichim, Timothy G. Dixon, James Veltmeyer, Kalina O'Connor
-
Publication number: 20220280574Abstract: The invention discloses compositions of matter, protocols, and therapeutic means for treatment of suicidal ideations and/or suppression of suicidal attempts. In one embodiment the invention provides the use of umbilical cord derived monocytes as a means of treatment. In another embodiment, monocytes are de-differentiated from adult monocytes using reprogramming means to create monocyte capable of producing anti-inflammatory as well as regenerative properties useful in reducing suicidal ideations and/or attempts.Type: ApplicationFiled: March 4, 2022Publication date: September 8, 2022Applicant: Therapeutic Solutions International, Inc.Inventors: Thomas E. Ichim, Timothy G. Dixon, Famela Ramos, Kalina O'Connor, James Veltmeyer
-
Publication number: 20220267730Abstract: Disclosed are means, methods and compositions of matter useful for induction of immunity towards cancer stem cells by providing a dendritic cell, wherein said dendritic cells express BORIS and/or peptides derived from BORIS, wherein said dendritic cell is cultured in the presence of one or more immunocytes. In one embodiment said dendritic cells are derived from umbilical cord blood sources and allogeneic to T cells, which are expanded ex vivo and used for the purposes of immunotherapy.Type: ApplicationFiled: February 22, 2022Publication date: August 25, 2022Applicant: Therapeutic Solutions International, Inc.Inventors: Thomas E. Ichim, Timothy G. Dixon, Feng LIN, Famela Ramos, James Veltmeyer
-
Publication number: 20220235325Abstract: Disclosed are means, methods, and compositions of matter useful for enhancement of dendritic cell activity. In one embodiment the invention provides the use of GABA agonists such as homotaurine for stimulation of dendritic cell activity. In one embodiment said dendritic cell activity is enhancement of natural killer cell activity and/or of T cell activity. In one embodiment NK cell activity is ability to induce cytotoxicity in neoplastically transformed cells, whereas T cell activity is either cytokine production for CD4 cells or cytotoxicity for CD8 cells.Type: ApplicationFiled: January 26, 2022Publication date: July 28, 2022Applicant: Therapeutic Solutions International, Inc.Inventors: Thomas Ichim, Timothy G. Dixon, James Veltmeyer, Famela Ramos
-
Publication number: 20220193127Abstract: Disclosed are means, methods and compositions of matter useful for reduction of brain inflammation and prevention of opioid addiction and/or tolerance. In one embodiment the invention provides utilization of platelet rich plasma (PRP), alone, or admixed with regenerative/anti-inflammatory adjuvants, for reduction of neural inflammation. In one embodiments PRP is admixed with oxytocin and administered intranasally in a patient at risk of opioid addiction. In another embodiment, PRP is admixed with fortified and non-fortified nigella sativa oil, and/or pterostilbene and administered intranasally. Other embodiments include utilization of autologous stromal vascular fraction cells alone and/or admixed with regenerative/anti-inflammatory adjuvants.Type: ApplicationFiled: December 20, 2021Publication date: June 23, 2022Applicant: Therapeutic Solutions International, Inc.Inventors: Thomas Ichim, Timothy G. Dixon, Famela Ramos, Wais Kaihani, James Veltmeyer, Kalina O'Connor